# Frequency Electronics Inc: Form 10-Q for the period ended Jan 31, 2024

- Company: [Frequency Electronics Inc](/companies/feim.md) (CIK 39020)
- Form: 10-Q
- Filed: 2024-03-18
- Accepted by EDGAR: Mar 18, 2024, 16:56 ET
- Period: 2024-01-31
- Accession: 0001185185-24-000269
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/39020/000118518524000269/freqelec20240131_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/39020/000118518524000269/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-01-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-11-01 to 2024-01-31 | $13.7m | us-gaap:Revenues |
| Revenue | 9 months, 2023-05-01 to 2024-01-31 | $39.7m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2023-11-01 to 2024-01-31 | $10.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2023-05-01 to 2024-01-31 | $27.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-11-01 to 2024-01-31 | $3.1m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2023-05-01 to 2024-01-31 | $12.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-11-01 to 2024-01-31 | $958.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-05-01 to 2024-01-31 | $2.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2023-11-01 to 2024-01-31 | $2.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2023-05-01 to 2024-01-31 | $7.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-11-01 to 2024-01-31 | −$473.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-05-01 to 2024-01-31 | $2.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-11-01 to 2024-01-31 | $27.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-05-01 to 2024-01-31 | $86.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-11-01 to 2024-01-31 | $6.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-05-01 to 2024-01-31 | $19.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-11-01 to 2024-01-31 | $130.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-05-01 to 2024-01-31 | $3.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2023-11-01 to 2024-01-31 | 9,439,939 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-05-01 to 2024-01-31 | 9,407,789 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-05-01 to 2024-01-31 | $1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-05-01 to 2024-01-31 | $671.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2023-05-01 to 2024-01-31 | $0 | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2024-01-31 | $11.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-01-31 | $52.1m | us-gaap:AssetsCurrent |
| Total assets | at 2024-01-31 | $77.7m | us-gaap:Assets |
| Current liabilities | at 2024-01-31 | $28.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-01-31 | $41.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-01-31 | $36.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,261 characters.

*“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:*

The statements in this Quarterly Report on Form 10-Q regarding future earnings and operations and other statements relating to the future constitute “forward-looking” statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include but are not limited to, our inability to integrate operations and personnel, actions by significant customers or competitors, general domestic and international economic conditions, reliance on key customers, including the U.S government, continued acceptance of the Company’s products in the marketplace, competitive factors, new products and technological changes, product prices and raw material costs, dependence upon third-party vendors, competitive developments, changes in manufacturing and transportation costs, the availability of capital, and the outcome of any litigation and arbitration proceedings. The factors listed above are not exhaustive. Other sections of this Form 10-Q and in Part I, Item 1A (Risk Factors) of the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2023 (the “Form 10-K”) include additional factors that could materially and adversely impact the Company’s business, financial condition and results of operations. Moreover, the Company operates in a very competitive and rapidly changing environment. New factors emerge from time to time and it is not possible for management to predict the impact of all these factors on the Company’s business, financial condition or results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not rely on forward-looking statements as a prediction of actual results. Any or all of the forward-looking statements contained in this Form 10-Q and any other public statement made by the Company or its management may turn out to be incorrect. The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

### Critical Accounting Policies and Estimates

The Company believes its most critical accounting policies to be the recognition of revenue and costs on production contracts and the valuation of inventory. Both of these areas require the Company to make use of reasonable estimates including estimating the cost to complete a contract, the realizable value of its inventory and the market value of its products. Changes in estimates can have a material impact on the Company’s financial position and results of operations. The Company’s significant accounting policies did not change during the three and nine months ended January 31, 2024.

#### Revenue Recognition

Revenues are reported in operating results predominantly over time using the cost-to-cost method. Under this method, revenue is recorded based upon the ratio that incurred costs bear to total estimated contract costs with related cost of revenues recorded as the costs are incurred. Each month management reviews estimated contract costs through a process of aggregating actual costs incurred and estimating additional costs to completion based upon the current available information regarding labor, outside services, materials, overhead costs, and status of the contract. The effect of any change in the estimated gross margin rate (“GM Rate”) for a contract is reflected in revenues in the period in which the change is known. Provisions for the full amount of anticipated losses on contracts are made in the period in which they become determinable.

Significant judgment is used in evaluating the financial information for certain contracts to determine an appropriate budget and estimated cost. The Company evaluates this information continuously and bases its judgments on historical experience, design specifications, and expected costs for material and labor.

#### Inventories

In accordance with industry practice, inventoried costs contain amounts relating to contracts and programs with long production cycles, a portion of which will not be realized within one year. Inventory write downs are established for slow-moving materials based on percentage of usage over a ten-year period, obsolete items on a gradual basis over five years with no usage and costs incurred on programs for which production-level orders cannot be determined as probable. Such write-downs are based upon management’s experience and estimates for future business. Any changes arising from revised estimates are reflected in cost of revenues in the period the revision is made.

### RESULTS OF OPERATIONS

The table below sets forth for the three and nine months ended January 31, 2024 and 2023, respectively, the percentage of consolidated revenues represented by certain items in the Company’s condensed consolidated statements of operations or notes to the condensed consolidated financial statements:

| Revenues | Three months Periods ended January 31, 2024 | 2023 | Nine months 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: |
| FEI-NY | 84.7% | 79.3% | 76.5% | 82.6% |
| FEI-Zyfer | 24.8 | 23.4 | 28.8 | 20.8 |
| Less intersegment revenues | (9.5) | (2.7) | (5.3) | (3.4) |
|  | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of revenues | 77.4 | 67.4 | 69.0 | 86.3 |
| Gross margin | 22.6 | 32.6 | 31.0 | 13.7 |
| Selling and administrative expenses | 19.1 | 22.2 | 18.8 | 23.0 |
| Research and development expenses | 7.0 | 7.4 | 5.8 | 9.0 |
| Operating (loss) income | (3.5) | 3.0 | 6.4 | (18.3) |
| Other income (loss), net | 4.4 | (6.0) | 1.2 | (2.4) |
| Provision for income taxes | - | - | - | - |
| Net income (loss) | 0.9% | (3.0)% | 7.6% | (20.7)% |

### Revenues

*(in thousands)*

| Segment | Three months Periods ended January 31, 2024 | 2023 | Change |  | Nine months 2024 | 2023 | Change |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| FEI-NY | $11,610 | $8,420 | $3,190 | 37.9% | $30,372 | $22,954 | $7,418 | 32.3% |
| FEI-Zyfer | 3,403 | 2,480 | 923 | 37.2 | 11,426 | 5,772 | 5,654 | 98.0 |
| Intersegment revenues | (1,299) | (280) | (1,019) | 363.9 | (2,100) | (953) | (1,147) | 120.4 |
|  | $13,714 | $10,620 | $3,094 | 29.1% | $39,698 | $27,773 | $11,925 | 42.9% |

For the three months ended January 31, 2024, revenues from commercial and U.S. Government communication satellite programs accounted for approximately 50% of consolidated revenues compared to approximately 47% of consolidated revenues during this same period in the prior fiscal year. Revenues are recognized primarily over time under the percentage-of-completion (“POC”) method. Revenues from the satellite market are recorded in the FEI-NY segment. Revenues from non-space U.S. Government/Department of Defense (“DOD”) customers, which are recorded in both the FEI-NY and FEI-Zyfer segments, accounted for approximately 44% of consolidated revenues for the three months ended January, 31, 2024 compared to approximately 47% of consolidated revenue during the same period in the prior fiscal year. Other commercial and industrial revenues for the three months ended January 31, 2024 accounted for approximately 7% of consolidated revenue compared to 6% in the same period of the prior fiscal year. The significant increase in revenue for this quarter, compared to the same quarter in the previous fiscal year, was reflected in both segments and primarily related to increases in government space of approximately $1.8 million in sales from space U.S. Government customers and approximately $1.0 million in sales from non-space U.S. government customers.

For the nine months ended January 31, 2024, revenues from commercial and U.S. Government communication satellite programs accounted for approximately 41% of consolidated revenues compared to approximately 46% of consolidated revenues during this same period in the prior fiscal year. Revenues are recognized primarily over time under the POC method. Revenues from the satellite market are recorded in the FEI-NY segment. Revenues from non-space U.S. Government/DOD customers, which are recorded in both the FEI-NY and FEI-Zyfer segments, accounted for approximately 53% of consolidated revenues for the nine months ended January, 31, 2024 compared to approximately 47% of consolidated revenue during the same period in the prior fiscal year. Other commercial and industrial revenues for the nine months ended January 31, 2024 accounted for approximately 6% of consolidated revenue compared to 7% in the same period of the prior fiscal year. The significant increase in revenue for this period, compared to the same period in the previous fiscal year, was reflected in both segments and primarily related to contract awards from prior periods that have moved into production.

### Gross Margin

*(in thousands)*

|  | Three months Periods ended January 31, 2024 | 2023 | Change |  | Nine months 2024 | 2023 | Change |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | $3,104 | $3,465 | $(361) | (10.4)% | $12,302 | $3,810 | $8,492 | 222.9% |
| Gross margin rate | 22.6% | 32.6% |  |  | 31.0% | 13.7% |  |  |

For the three months ended January 31, 2024, gross margin (“GM”) decreased and GM Rate decreased compared to the same period in the prior fiscal year. The GM dollars and the GM Rate decreased due to un-anticipated costs associated with fixed price and customer funded new product development. For the nine months ended January 31, 2024, GM and GM Rate increased compared to the same period in the prior fiscal year. Despite the issue noted above with respect to the new product development costs during the quarter ended January 31, 2024, the increase in GM and GM Rate during the nine months ended January 31, 2024 were due to the fact that many of the technical challenges faced in the prior fiscal year period have been resolved and, as a result, the related programs are now moving forward and running more efficiently. Previous programs that sustained lower margins due to technical issues are near completion, or have been completed.

### Selling, General, and Administrative Expenses

*Periods ended January 31,*

*(in thousands)*

| Three months 2024 | 2023 | Change |  | Nine months 2024 | 2023 | Change |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| $2,619 | $2,357 | $262 | 11.1% | $7,473 | $6,383 | $1,090 | 17.1% |

For the three months ended January 31, 2024 and 2023, selling, general, and administrative (“SG&A”) expenses were approximately 19% and 22%, respectively, of consolidated revenues. The percentage of consolidated revenue decreased 3% due to an increase in sales for the three months ended January 31, 2024 as compared to the three months ended January 31, 2023. Similarly, the absolute increase in SG&A expenses for the three months ended January 31, 2024, as compared to the prior year period, was driven by increased bid/proposal costs associated with the increased sales.

For the nine months ended January 31, 2024 and 2023, SG&A expenses were approximately 19% and 23%, respectively, of consolidated revenues. The percentage of consolidated revenue decreased 4% due to an increase in sales for the nine months ended January 31, 2024 as compared to the nine months ended January 31, 2023. Similarly, the absolute increase in SG&A expenses for the nine months ended January 31, 2024 as compared to the prior year period was largely due to bid/proposal cost associated with increased sales and an increase in professional fees and payroll associated costs.

### Research and Development Expenses

*Periods ended January 31,*

*(in thousands)*

| Three months 2024 | 2023 | Change |  | Nine months 2024 | 2023 | Change |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| $958 | $783 | $175 | 22.3% | $2,304 | $2,492 | $(188) | (7.5)% |

Research and Development (“R&D”) expenditures represent investments intended to keep the Company’s products at the leading edge of time and frequency technology and enhance future competitiveness. The change in R&D expenditures for the three and nine months ended January 31, 2024, as compared to the prior year quarter, was primarily due to a temporary shift of R&D focus. The Company plans to continue to invest in R&D in the future to keep its products at the state of the art.

### Operating Income (Loss)

*Periods ended January 31,*

*(in thousands)*

| Three months 2024 | 2023 | Change |  | Nine months 2024 | 2023 | Change |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| $(473) | $325 | $(798) | (245.5)% | $2,525 | $(5,065) | $7,590 | 149.9% |

For the three months ended January 31, 2024, operating income decreased due to the design issue relating to a new product development. For the nine months ended January 31, 2024, operating income increased despite the temporary design issue, due to a combination of increased revenue and GM, and the effects of certain cost cutting measures instituted by management that began in fiscal year 2023.

### Other Income (Expense), net

*(in thousands)*

|  | Three months Periods ended January 31, 2024 | 2023 | Change |  | Nine months 2024 | 2023 | Change |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Investment income (expense) , net | $636 | $(625) | $1,261 | 201.8% | $549 | $(600) | $1,149 | 191.5% |
| Interest expense | (27) | (18) | (9) | 50.0% | (86) | (81) | (5) | 6.2% |
| Other income (expense), net | - | 5 | (5) | (100.0)% | - | 5 | (5) | (100.0)% |
|  | $609 | $(638) | $1,247 | (195)% | $463 | $(676) | $1,139 | (168)% |

Other income (expense), net is derived from various sources. The income can come from reclaiming of metal, refunds, interest on deferred trust assets, or the sale of a fixed asset. Interest expense is related to the deferred compensation payments made to retired employees. The majority of the approximately $0.6 million of investment income for the three months ended January 31, 2024 was from the proceeds from a life insurance plan. The increase in investment income for the nine months ended January 31, 2024, likewise reflected the proceeds from this same life insurance plan.

### Provision for Income Tax

*Periods ended January 31,*

*(in thousands)*

| Three months 2024 | 2023 | Change |  | Nine months 2024 | 2023 | Change |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| $6 | $3 | $3 | 100.0% | $19 | $6 | $13 | 216.7% |

|  | Three months Periods ended January 31, 2024 | 2023 | Nine months 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: |
| Effective tax rate on pre-tax book income (loss): | 4.4% | (1.1)% | 0.6% | (0.1)% |

The estimated annual effective tax rate for the fiscal year ending April 30, 2024 is 0.4%. This calculation reflects estimated income tax expense based on our current year annual pretax income forecast which is offset by the estimated change in the current year valuation allowance. The Company maintains a full valuation allowance against its deferred tax assets.

For the three months ended January 31, 2024, the Company recorded an income tax provision of $6,000 primarily related to state income taxes and discrete income tax provision related to an accrual of interest for unrecognized tax benefits. For the three months ended January 31, 2023, the Company recorded an income tax provision of $3,000.

For the nine months ended January 31, 2024, the Company recorded an income tax provision of $19,000 primarily related to state income taxes and discrete income tax provision related to an accrual of interest for unrecognized tax benefits. For the nine months ended January 31, 2023, the Company recorded an income tax provision of $6,000.

The effective tax rate for the three months ended January 31, 2024 was an income tax provision of 4.4% on pretax income of $0.1 million compared to an income tax provision of (1.1)% on pretax loss of $0.3 million in the comparable prior fiscal year period. The effective tax rate for the three months ended January 31, 2024 differs from the U.S. federal statutory rate of 21% primarily due to domestic losses for which the Company is not recognizing an income tax benefit.

The effective tax rate for the nine months ended January 31, 2024 was an income tax provision of 0.6% on pretax income of $3.0 million compared to an income tax provision of (0.1)% on pretax loss of $5.7 million in the comparable prior fiscal year period. The effective tax rate for the nine months ended January 31, 2024 differs from the U.S. federal statutory rate of 21% primarily due to domestic losses for which the Company is not recognizing an income tax benefit.

The Inflation Reduction Act of 2022 (the “Act”) was signed into U.S. law on August 16, 2022. The Act includes various tax provisions, including an excise tax on stock repurchases, expanded tax credits for clean energy incentives, and a corporate alternative minimum tax that generally applies to U.S. corporations with average adjusted annual financial statement income over a three-year period in excess of $1 billion. The Company does not expect the Act to materially impact its consolidated financial statements.

### LIQUIDITY AND CAPITAL RESOURCES

The Company’s consolidated balance sheets continue to reflect a strong working capital position of approximately $24.1 million at January 31, 2024 and $21.0 million at April 30, 2023. Included in working capital at January 31, 2024 and April 30, 2023 was $11.7 million and $12.0 million, respectively, of cash and cash equivalents. The Company’s current ratio was 1.9 to 1 at January 31, 2024 compared to 1.8 to 1 as of April 30, 2023.

Net cash provided by operating activities for the nine months ended January 31, 2024 and 2023 was approximately $1.2 million and $1.9 million, respectively. The decrease in net cash provided by operating activities in the first nine months of fiscal 2024 as compared to the prior fiscal year period was mainly due to operating income, offset by an increase in inventories. For the nine months ended January 31, 2024 and 2023, the Company incurred approximately $3.1 million and $2.7 million, respectively, of non-cash operating expenses including amortization of ROU assets, depreciation and amortization, inventory net realizable value adjustments, deferred compensation, and accruals for employee benefit programs.

Net cash used in investing activities for the nine months ended January 31, 2024 was approximately $0.7 million compared to net cash provided by investing activities of approximately $8.7 million for the nine months ended January 31, 2023. During the nine months ended January 31, 2024, no marketable securities were sold or redeemed compared to $11.0 million for the same period of fiscal year 2023. During the nine months ended January 31, 2024, no marketable securities were purchased compared to $1.4 million for the same period of fiscal year 2023. The Company acquired property, plant, and equipment in the amount of approximately $0.7 million and $0.9 million for the nine month periods ended January 31, 2024 and 2023, respectively.

There were no financing activities for the nine months ended January 31, 2024. Net cash used in financing activities for the nine months ended January 31, 2023 was approximately $9.4 million related to a dividend payout.

The Company has been authorized by its Board of Directors to repurchase up to $5.0 million worth of shares of its common stock when appropriate opportunities arise. As of January 31, 2024, the Company has repurchased approximately $4.0 million of its common stock out of the $5 million authorization, the majority of which has since been reissued. For the nine months ended January 31, 2024 and 2023, there were no repurchases of shares.

The Company will continue to expend resources for R&D to develop, improve and acquire products for space applications, guidance and targeting systems, and communication systems that management believes will result in future growth and profitability. The Company anticipates securing additional customer funding for a portion of its R&D activities and will allocate internal funds depending on market conditions and identification of new opportunities. The Company expects internally generated cash will be adequate to fund these R&D efforts. The Company may also pursue acquisitions to expand its range of products and may use internally generated cash and external funding in connection with such acquisitions.

As of January 31, 2024, the Company’s consolidated funded backlog was approximately $67 million compared to $57 million at April 30, 2023, the end of fiscal year 2023. Approximately 74% of this backlog is expected to be realized in the next twelve months. The Company excludes from backlog any contracts or awards for which it has not received authorization to proceed. On fixed price contracts, the Company excludes any unfunded portion. Over time, as partially funded contracts become fully funded, the Company will add the additional funding to its backlog. The backlog is subject to change for various reasons, including possible cancellation of orders, change orders, terms of the contracts and other factors beyond the Company’s control. Accordingly, the backlog is not necessarily indicative of future revenues or profits (losses) which may be realized when the results of such contracts are reported.

The Company believes that its liquidity is adequate to meet its short-term operating and investment needs through at least March 18, 2025 and its long-term operation and investment needs for the foreseeable future thereafter.

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

## Controls and procedures

As filed, 1,440 characters.

#### Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on their evaluation, the Company’s chief executive officer and chief financial officer have concluded that, as of January 31, 2024, the Company’s disclosure controls and procedures were effective at a reasonable assurance level.

There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

#### Changes in Internal Control Over Financial Reporting

There have been no changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended January 31, 2024 that has materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 339 characters.

As disclosed in “Item 1A. Risk Factors” in the Form 10-K, there are a number of risks and uncertainties that could have a material adverse effect on the Company’s business, financial position, results of operations and/or cash flows. There are no material updates or changes to the Company’s risk factors since the filing of the Form 10-K.

Filed Mar 18, 2024.
Source: SEC EDGAR, the filing index for accession 0001185185-24-000269. Last ingested by Listed: Nov 5, 2026, 18:05 ET. No prices; not investment advice.
